ESBLs阳性肺炎克雷伯菌的研究进展  

Research progress on ESBLs positive Klebsiella pneumoniae

作　　者：丁嘉雯 李娜[1] Ding Jiawen;Li Na(Department of Clinical Laboratory,Binzhou Medical University Hospital,Binzhou 256600,China)

机构地区：[1]滨州医学院附属医院检验科,滨州256600

出　　处：《国际医药卫生导报》2024年第7期1071-1074,共4页International Medicine and Health Guidance News

摘　　要：肺炎克雷伯菌为革兰阴性菌,属于肠杆菌科,兼性厌氧,常寄殖于人体上呼吸道和肠道内,是重要的条件致病菌和院内感染常见的病原体之一。近年来,由于抗菌药物的不合理使用等原因,其耐药性逐年升高。超广谱β-内酰胺酶(extended-spectrumβ-lactamases,ESBLs)是20世纪80年代以来发现的β-内酰胺酶,是肺炎克雷伯菌耐药的主要原因之一。本文综述了产ESBLs肺炎克雷伯菌的耐药基因、分型及同源性分析,以期为预防ESBLs阳性肺炎克雷伯菌所致肺炎的发生和临床治疗中抗生素的合理使用提供参考。Klebsiella pneumoniae is a Gram-negative bacteria,belongs to Enterobacteriaceae,is facultally anaerobic,and often colonizes on the human upper respiratory tract and intestinal tract.It is an important opportunistic pathogen and one of the common pathogens of nosocomial infection.In recent years,due to the irrational use of antibiotics and other reasons,the drug resistance has been increasing year by year.The extended-spectrumβ-lactamases(ESBLs),discovered since the 1980s,are one of the main causes of drug resistance of Klebsiella pneumoniae.In this paper,the drug resistance genes,typing and homology analysis ESBLs-producing Klebsiella pneumoniae are reviewed,so as to provide references for the prevention of ESBL-positive Klebsiella pneumoniae pneumonia and rational use of antibiotics in clinical treatment.

关 键 词：肺炎克雷伯菌 超广谱Β-内酰胺酶 耐药基因 分型 同源性分析 进展 

分 类 号：R378[医药卫生—病原生物学]